Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc.

AMPH

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

$21.59

−$0.08 · -0.37%

Aug 21, 3:55 PM ET

AMPH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

83

Deep Value

Momentum

26

Weakening

Sentiment

64

Bullish

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Yongfeng Zhang
Listed since
Jun 25, 2014
Employees
1,976

Market position

Volume
376.56K
0.67× average
Average volume
564.79K
Average daily volume
Market cap
952.41M USD
Beta
0.9
Market reference 1

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+4.85%
11 comparable reports
Latest EPS result
0.91
Estimate 0.62 · Beat by 46.77%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.060.830.60.37Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.92, estimate 1.01, surprise -8.91%, Miss. Q2 2025, reported May 7, 2025: actual 0.74, estimate 0.66, surprise +12.12%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.85, estimate 0.71, surprise +19.72%, Beat. Q4 2025, reported Nov 6, 2025: actual 0.93, estimate 0.77, surprise +20.78%, Beat. Q1 2026, reported Feb 26, 2026: actual 0.73, estimate 0.903, surprise -19.16%, Miss. Q2 2026, reported May 7, 2026: actual 0.42, estimate 0.7, surprise -40.00%, Miss. Q3 2026, reported Aug 6, 2026: actual 0.91, estimate 0.62, surprise +46.77%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.864, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates205.77M191.38M177M162.61MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 186.52M USD, estimate 188.78M USD, surprise -1.19%, Miss. Q2 2025, reported May 7, 2025: actual 170.53M USD, estimate 173.06M USD, surprise -1.46%, Miss. Q3 2025, reported Aug 7, 2025: actual 174.41M USD, estimate 177.1M USD, surprise -1.52%, Miss. Q4 2025, reported Nov 6, 2025: actual 191.84M USD, estimate 190.48M USD, surprise +0.71%, Beat. Q1 2026, reported Feb 26, 2026: actual 183.11M USD, estimate 188.77M USD, surprise -3.00%, Miss. Q2 2026, reported May 7, 2026: actual 171.17M USD, estimate 173.46M USD, surprise -1.32%, Miss. Q3 2026, reported Aug 6, 2026: actual 183.9M USD, estimate 179.92M USD, surprise +2.21%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 197.85M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings
Strong buy00%
Buy325%
Hold867%
Sell18%
Strong sell00%

Recent analyst actions

7 institutions
JefferiesdowngradeBuyHold
JP MorgandowngradeOverweightNeutral

AMPH peers

Continue in GoAI

Research AMPH

research.disclaimer